US2002035128A1PendingUtilityA1
Methods for treating parkinson's disease
Priority: Mar 3, 2000Filed: Jul 6, 2001Published: Mar 21, 2002
Est. expiryMar 3, 2020(expired)· nominal 20-yr term from priority
Inventors:Raymond Pratt
A61P 25/28A61K 31/445A61P 25/00A61P 25/16
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides methods for treating Parkinson's disease by administering a therapeutically effective amount of at least one cholinesterase inhibitor compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. A preferred cholinesterase inhibitor compound is donepezil, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating Parkinson's disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of formula IV or a pharmaceutically acceptable salt thereof,
wherein the compound of formula IV is: or a stereoisomer thereof.
2 . The method of claim 1 , wherein the pharmaceutically acceptable salt of the compound of formula IV is a hydrochloride salt.
3 . The method of claim 1 , wherein the stereoisomer of the compound of formula IV is a compound of formula VII or a pharmaceutically acceptable salt thereof,
wherein the compound of formula VII is:
4 . The method of claim 3 , wherein the pharmaceutically acceptable salt of the compound of formula VII is a hydrochloride salt.
5 . The method of claim 1 , wherein the stereoisomer of the compound of formula IV is a compound of formula VIII or a pharmaceutically acceptable salt thereof,
wherein the compound of formula VIII is:
6 . The method of claim 5 , wherein the pharmaceutically acceptable salt of the compound of formula VIII is a hydrochloride salt.
7 . The method of claim 1 , wherein the compound of formula IV, the pharmaceutically acceptable salt thereof, or the stereoisomer thereof is administered in an amount of about 5 milligrams.
8 . The method of claim 1 , wherein the compound of formula IV, the pharmaceutically acceptable salt thereof, or the stereoisomer thereof is administered in an amount of about 10 milligrams.
9 . The method of claim 1 , wherein the compound of formula IV, the pharmaceutically acceptable salt thereof, or the stereoisomer thereof is orally administered to the patient.
10 . The method of claim 1 , wherein the compound of formula IV, the pharmaceutically acceptable salt thereof, or the stereoisomer thereof is in the form of a tablet.Join the waitlist — get patent alerts
Track US2002035128A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.